IDiyas

For the Inventor, By the Inventor

Madison, CT, United States of America

David W Smith

USPTO Granted Patents = 14

Average Co-Inventor Count = 3.5

ph-index = 7

Forward Citations = 246(Granted Patents)


Location History:

  • Evansville, IN (US) (1986)
  • Clinton, CT (US) (1990 - 1995)
  • Madison, CT (US) (1995 - 2006)

Company Filing History:

goldMedal12 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal1 out of 637 
 
Bristol-myers Company
 patents
bronzeMedal1 out of 4,770 
 
Merck + Co., Inc.
 patents
4. 1 out of 142 
 
Mead Johnson & Company
 patents
where one patent can have more than one assignee

Years Active: 1986-2006

Loading Chart...
14 patents (USPTO):Explore Patents
1. 6989399 - Antiamyloid phenylsulfonamides: N-alkanol derivatives (2006-01-24),
2. 6967196 - Sulfonamide compounds and uses thereof (2005-11-22),
3. 5763444 - Antidepressant 1-arylalkyl-4-(alkoxy pyridinyl)-and (1998-06-09),
4. 5703129 - 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of (1997-12-30),
5. 5618816 - Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and (1997-04-08),
6. 5521188 - Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and (1996-05-28),
7. 5472966 - Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines (1995-12-05),
8. 5434154 - Antimigraine 4-pyrimidinyl and pyridinyl derivatives of (1995-07-18),
9. 5382592 - Antimigraine cyclobutenedione derivatives of tryptamines (1995-01-17),
10. 5300506 - Indolylalkyl derivatives of pyrimidinylpiperazine for treating vascular (1994-04-05),
11. 5077293 - 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines (1991-12-31),
12. 4954502 - 1-indolyalkyl-4-(substituted-pyridinyl)piperazines (1990-09-04),
13. 4613600 - Antidepressant 1,2,4-triazolone compounds (1986-09-23),
14. 4590196 - Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives (1986-05-20),

Title: The Innovative Contributions of David W. Smith

Introduction

David W. Smith is a notable inventor based in Madison, Connecticut, with a remarkable portfolio of 14 patents. His work primarily focuses on the development of pharmaceutical compounds aimed at treating diseases characterized by amyloid deposition, such as Alzheimer's Disease.

Latest Patents

Among his latest patents, Smith has developed a series of N-alkanol-N-phenyl benzenesulfonamide derivatives. These compounds are designed to inhibit the production of β-amyloid peptide, which is crucial in the treatment of Alzheimer's Disease. Additionally, he has introduced a novel class of sulfonamide compounds that contain a core sulfonamide group. These compounds have variable moieties that can modulate the production of amyloid β protein, making them useful in preventing or treating various diseases.

Career Highlights

Smith has had a distinguished career, working with prominent companies such as Bristol-Myers Squibb Company and Bristol-Myers Company. His contributions to the field of pharmaceuticals have been significant, particularly in the development of compounds that address critical health issues.

Collaborations

Throughout his career, Smith has collaborated with esteemed colleagues, including Joseph P. Yevich and Edward H. Ruediger. These partnerships have further enhanced his innovative work and contributions to the pharmaceutical industry.

Conclusion

David W. Smith's innovative contributions to the field of pharmaceuticals, particularly in the development of compounds for treating Alzheimer's Disease, highlight his significant impact as an inventor. His extensive patent portfolio and collaborations underscore his dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…